• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Savara (SVRA), What Is Drawing Fresh Attention To The Biotech Now?

    Simply Wall St·10/09/2026 12:35:37
    Listen to the news

    Savara (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, has drawn attention after recent price pressure, with the stock down over the past week, month, and past three months.

    Despite the recent slide, the share price is still well above where long term holders started. However, shorter term momentum is clearly fading as the stock fell over the past quarter, while the 1 year total shareholder return sits at 41.23% and the 5 year total shareholder return at 274.42%.

    Scan beyond Savara and pressure-tested biotechs with recent pullbacks by reviewing our curated 20 high quality undiscovered gems that still pair strong fundamentals with under-the-radar pricing.

    Savara has just given back a chunk of recent gains, which tempts some investors to buy the dip while others wait for a deeper pullback. Which camp does the current valuation really support next?

    Preferred Price-to-Book Multiple of 8.5x: Is It Justified?

    Valuation on Savara currently leans heavily on its P/B ratio, with the stock trading at 8.5x book value against a last close of $4.83, which places it at a rich level compared to both peers and the broader US biopharma space.

    The price-to-book multiple compares the market value of the equity to the net assets on the balance sheet. For a clinical stage biotech with limited current revenue and ongoing losses, investors often lean on P/B because there are no stable earnings to feed into P/E or cash flow based ratios.

    In Savara's case, the headline numbers show that this P/B is on the expensive side. The stock trades at 8.5x book value, while the US Biotechs industry average is 2.1x and a narrower peer set averages 6.2x. That is a strong premium, which suggests the market is pricing in a relatively optimistic path for the molgramostim program and future profitability, even though there is currently insufficient data to run a full SWS DCF model and the business is still loss making with a negative return on equity.

    Given that gap, the valuation currently reflects a higher expectation than what the balance sheet alone would justify when stacked directly against sector benchmarks.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 8.5x (OVERVALUED).

    Still, the story can change quickly if clinical data for molgramostim disappoints or if ongoing losses deepen from the current US$139.309 million net loss.

    Find out about the key risks to this Savara narrative.

    Next Steps

    Sentiment around Savara is clearly split, which is exactly why checking the underlying data yourself matters. Move quickly, review the full mix of potential downsides and upside drivers, and weigh the 1 key reward and 2 important warning signs

    Ready to act on your next idea beyond Savara?

    Do not stop with a single ticker. Turn this research mindset into a habit and keep sharpening your watchlist with focused, data driven ideas built from clear fundamentals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.